Cagrisema
5 mg
Cagrilintide + Semaglutide Blend
Cagrisema
Amylin analogue + GLP-1 agonist blend for dual-pathway metabolic research.
Prices in AUD. Tax included.
Research Use Only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Description
Cagrisema is a combination research peptide containing Cagrilintide (an amylin analogue) and Semaglutide (a GLP-1 agonist). This blend targets two distinct satiety pathways — amylin-mediated hindbrain signaling and GLP-1-mediated hypothalamic pathways — offering researchers a tool to study synergistic metabolic effects.
Specifications
- SKU
- CAGRI-5MG
- Size
- 5 mg
- Form
- Lyophilised Powder
- Purity
- >99%
- Storage
- -20°C (lyophilised), 2-8°C (reconstituted)
- Shipping
- Australia Post — 3–5 business days
Research Summary
Published data indicates the combination of amylin and GLP-1 pathway activation produces greater reductions in food intake than either agent alone in preclinical models. The amylin component adds a complementary mechanism via area postrema activation.
Testing Protocol
- HPLC Purity Analysis
- Mass Spectrometry Identity Verification
- Endotoxin Screening (LAL Test)